|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis显示文摘AIM:To study the efficacy, safety, and feasibility of a granulocyte adsorptive type apheresis system for the treatment of patients with chronically active ulcerative colitis despite standard therapy.METHODS: An open label multicenter study was carried out in 39 patients with active ulcerative colitis (CAI6-8) despite continuous use of steroids (a minimum total dose of 400 mg prednisone within the last 4 wk).Patients received a total of five aphereses using a granulocyte adsorptive technique (Adacolumn(R), Otsuka Pharmaceutical Europe, UK). Assessments at wk 6 and during follow-up until 4 mo comprised clinical (CAI) and endoscopic (EI) activity index, histology, quality of life(IBDQ), and laboratory tests.RESULTS: Thirty-five out of thirty-nine patients were qualified for intent-to-treat analysis. After the apheresis treatment at wk 6, 13/35 (37.1%) patients achieved clinical remission and 10/35 (28.6%) patients had endoscopic remission (CAI<4, EI<4). Quality of life (IBDQ) increased significantly (24 points, P<0.01)at wk 6. Apheresis could be performed in all but one patient. Aphereses were well tolerated, only one patient experienced anemia.CONCLUSION: In patients with steroid refractory ulcerative colitis, five aphereses with a granulocyte/monocyte depleting filter show potential short-term efficacy. Tolerability and technical feasibility of the procedure are excellent. | Wolfgang Kruis Axel Dignass Elisabeth Steinhagen-Thiessen Julia Morgenstern Joachim M(o|¨)ssner Stephan Schreiber Maurizio Vecchi Alberto Malesci Max Reinshagen Robert L(o|¨)fberg | 2005 | World Journal of Gastroenterology2005，11，44： | 4 |
| 2 | Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011 – Ergebnisse einer Evidenzbasierten Konsensuskonferenz显示文摘 | A. Dignass J. Prei? D. Aust F. Autschbach A. Ballauff G. Barretton B. Bokemeyer S. Fichtner-Feigl S. Hagel K. Herrlinger G. Jantschek A. Kroesen W. Kruis T. Kucharzik J. Langhorst M. Reinshagen G. Rogler D. Schleiermacher C. Schmidt S. Schreiber H. Schulz | 2011 | Z Gastroenterol2011，，09： | 2 |
| 3 | Parameters of a severe disease course in ulcerative colitis显示文摘AIM:To detect high risk patients with a progressive disease course of ulcerative colitis(UC) requiring immunosuppressive therapy(IT).METHODS:A retrospective,multicenter analysis of 262 UC patients from eight German tertiary inflammatory bowel disease centres was performed.Patients were divided into two groups depending on the patients need to initiate immunosuppressive therapy in the disease course.A comparison between the two groups was made with regard to demographics,clinical and laboratory parameters obtained within three months after UC diagnosis and the response to first medical therapy.Using this data,a prognostic model was established to predict the individual patients probability of requiring an immunosuppressive therapy.RESULTS:In 104(39.7%) out of 262 patients,UC therapy required an immunosuppressive treatment.Patients in this group were significantly younger at time of diagnosis(HR = 0.981 ± 0.014 per year,P = 0.009),and required significantly more often a hospitalisation(HR = 2.5 ± 1.0,P < 0.001) and a systemic corticosteroid therapy at disease onset(HR = 2.4 ± 0.8,P < 0.001),respectively.Response to steroid treatment was significantly different between the two groups of patients(HR = 5.2 ± 3.9 to 50.8 ± 35.6 compared to no steroids,P = 0.016 to P < 0.001).Furthermore,in the IT group an extended disease(HR = 3.5 ± 2.4 to 6.1 ± 4.0 compared to proctitis,P = 0.007 to P = 0.001),anemia(HR = 2.2 ± 0.8,P < 0.001),thrombocytosis(HR = 1.9 ± 1.8,P = 0.009),elevated C-reactive protein(CRP)(HR = 2.1 ± 0.9,P < 0.001),and extraintestinal manifestations in the course of disease(HR = 2.6 ± 1.1,P = 0.004) were observed.Six simple clinical items were used to establish a prognostic model to predict the individual risk requiring an IT.This probability ranges from less than 2% up to 100% after 5 years.Using this,the necessity of an immunosuppressive therapy can be predicted in 60% of patients.Our model can determine the need for an immunosuppressive drug therapy or if a 'watch and wait' approach is reasonable already early in the treatment course of UC.CONCLUSION:Using six simple clinical parameters,we can estimate the patients individual risk of developing a progressive disease course. | Andreas Stallmach Luisa Nickel Thomas Lehmann Bernd Bokemeyer Martin Bürger Dietrich Hüppe Wolfgang Kruis Susanna Nikolaus Jan C Preiss Andreas Sturm Niels Teich Carsten Schmidt | 2014 | World Journal of Gastroenterology2014，20，35： | 2 |
| 4 | Acute hepatitis induced by an Aloe vera preparation: A case report显示文摘AIM: Aloe vera, plant extracts of Aloe barbadensis miller,is widely used in phytomedicine. The first case of acute hepatitis due to this compound was described.METHODS: Description of a clinical case.RESULTS: Hepatitis in a 57-year old female could be linked to the ingestion of Aloe barbadensis miller compounds. The patient's hepatitis resolved completely after discontinuing this medication.CONCLUSION: The case emphasizes the importance of considering phytopharmaceutical over-the-counter drugs as causative agents of hepatitis. | Christian Rabe Annemarie Musch Peter Schirmacher Wolfgang Kruis Robert Hoffmann | 2005 | World Journal of Gastroenterology2005，11，2： | 2 |
| 5 | European evidence-based Consensus on the management of ulcerative colitis: Current management显示文摘 | S.P.L. Travis E.F. Stange M. Lémann T. ?resland W.A. Bemelman Y. Chowers J.F. Colombel G. D'Haens S. Ghosh P. Marteau W. Kruis N.J.McC. Mortensen F. Penninckx M. Gassull | 2008 | Journal of Crohn’s and Colitis2008，，1： | 2 |
| 6 | Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis显示文摘 | Brandes JW Schreiber S | 1998 | Aliment Pharmacol Ther1998，12，8： | 1 |
| 7 | Maintaining remission of ulcerative colitis with the prohiotic escherichia coil nissle 1917 is as effective as with standard mesalazine 显示文摘 | Kruis W Fric P Pokrotnieks J | 2004 | Gut2004，53，11： | 1 |
| 8 | Interleukin4 and -13 inhibit tumor necrosis factor-α mRNA translational activation in li- popolysaccharide-induced mouse macrophages 显示文摘 | Mijatovic T Kruys V Caput D | 1997 | J Biol Chem1997，272，14： | 1 |
| 9 | Once daily versus three times daily mesalazine granules in active ulcerative colitis: A doube-blind, double-dummy, randomised, non-inferiority trial 显示文摘 | Kruis W Kiudelis G Racz I | 2009 | Gut2009，58，2： | 1 |
| 10 | Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine显示文摘 | Kruis W Fric P Pokrotnieks J | 2004 | Gut2004，53，11： | 1 |
| 11 | Double-blind comparison of an oral Escherichia coliprepration and mesalazine in maintaining remission of ulcerative colitis显示文摘 | Kruis W Schtz E Fric P | 1997 | Aliment Pharmacol Ther1997，11，： | 1 |
| 12 | Maintaining remission of ulcerative colitis with the probiotic Eschefichia call Nissle 1917 is as effective as with standard mesalazine显示文摘 | Kruis W Fric P Pokrotnieks J | 2004 | Gut2004，53，11： | 1 |
| 13 | Interleukin-4 and-13 inhibit tumor necrosis factor-alpha mRNA translational activation in lipopolysaccharide-induced mouse macrophages显示文摘 | Mijatovic T Kruys V Caput D | 1997 | J Biol Chem1997，272，14： | 1 |
| 14 | Interferon-producing cells fail to induce proliferation of native T cells but can promote expansion and T helper 1 differention of antigen-experienced unpolarized T cells显示文摘 | Kruy A Veeraswamy R Pekosz A | 2003 | J Exp Med2003，197，7： | 1 |
| 15 | Bowel preparation for colo- noscopy with sodium phosphate solution versus polyethylene glycol-based lavage:a multicenter trial 显示文摘 | Schanz S Kruis W Mickisch O | 2008 | Diagn Ther Endosc2008，2008，71： | 1 |
| 16 | A simple model for the evolution of the characteristics of aggregate particles undergoing coagulation and sintering显示文摘 | KRUIS F E KUSTERS K A PRATSINIS S E | 1993 | Aerosol Sci and Tech1993，19，： | 1 |
| 17 | Pregabalin in patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen显示文摘 | J.H. Vranken M.G.W. Dijkgraaf M.R. Kruis M.H. van der Vegt M.W. Hollmann M. Heesen | 2007 | Pain2007，，： | 1 |
| 18 | A simple model forthe evolution of the characteristics of aggregate particlesundergoing coagulation and sintering显示文摘 | Kruis F E Kusters K A Pratsinis S E | 1993 | Aerosol Scienceand Technology1993，19，4： | 1 |
| 19 | Chronic inflammatiory bowel disease and cancer显示文摘 | Pohl C Hombach A and Kruis W | 2000 | Hepatogastroenterology2000，47，： | 1 |
| 20 | Double - blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis显示文摘 | Kruis W Schtitz E Frie P | 1997 | Aliment Phar- macol Ther1997，11，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员